Study start date is on Nov 27th 2024.
A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.
initial echocardiogram ejection fraction less than 40%
follow up echocardiogram ejection fraction over 50% and LVEDD index normal range
NTprobnp criteria
eGFR ≥60 ; less 440
under age 18 year
uncontrolled BP ( over 150/90)
coronary revascularization within 6 months
significant valve disease